Skip to main content

Advertisement

The effect of infliximab on rheumatoid factor and anti-citrullinated cyclic peptide antibodies

Article metrics

  • 3442 Accesses

Background

Rheumatoid arthritis (RA) patients are successfully treated with infliximab (anti-TNF-α therapy). This therapy may induce autoantibodies like anti-dsDNA antibodies.

Objectives

To investigate the effect of infliximab on rheumatoid factor (RF) and anti-citrullinated cyclic peptide antibodies (anti-CCP antibodies).

Patients and methods

62 patients with refractory RA were treated with infliximab in an early access program. They received 3 mg/kg infliximab IV at week 0, 2, 6 and every 8 weeks thereafter in combination with MTX. Serum samples were obtained at baseline and week 30. Samples were tested for RF Waaler-Rose (SERODIA-RA, Fujirebio Inc), RF Latex Fixation (DifcoLaboratories) and anti-CCP antibodies ELISA (Euro-Diagnostica).

Results

At baseline, 41/62 RA patients were positive for RF Waaler-Rose, 39/62 RA patients were positive for RF Latex Fixation and 41/62 RA patients had a positive test result for anti-CCP antibodies ELISA. After infliximab treatment, 33/62 RA patients were positive for RF Waaler-Rose, 31/62 RA patients were positive for RF Latex Fixation and we observed a positive test result for anti-CCP antibodies in the same 41/62 RA patients. McNemar test revealed a significant paired difference for RF Waaler-Rose (P = 0.039) and for RF Latex Fixation (P = 0.021), but not for anti-CCP antibodies (P = 1.0). Wilcoxon Signed Rank Test showed a significant decrease for RF Waaler-Rose (P < 0.001) and for RF Latex Fixation (P = 0.035). No significant difference was observed for anti-CCP antibodies (P = 0.744).

Conclusion

In RA patients, infliximab treatment results in a decrease of RF Waaler-Rose and RF Latex Fixation. No difference considering the anti-CCP antibodies is seen.

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

van Damme, N., de Rycke, L., Kruithof, E. et al. The effect of infliximab on rheumatoid factor and anti-citrullinated cyclic peptide antibodies. Arthritis Res Ther 4, 72 (2002) doi:10.1186/ar517

Download citation

Keywords

  • Peptide
  • Rheumatoid Arthritis
  • Arthritis
  • Serum Sample
  • Infliximab